Elsevier

Brain Research

Volume 1476, 2 October 2012, Pages 183-202
Brain Research

Review
From α-synuclein to synaptic dysfunctions: New insights into the pathophysiology of Parkinson's disease

https://doi.org/10.1016/j.brainres.2012.04.014Get rights and content

Abstract

Alpha-synuclein is a natively unfolded protein playing a key role in the regulation of several neuronal synaptic functions in physiological and pathological conditions. Many studies, over the past years, have shown that it is actively involved in PD pathophysiology. Alpha-synuclein is integrated in a complex network of neuronal processes through the interaction with cytosolic and synaptic proteins. Hence, it is not the sole α-synuclein pathology but its effects on diverse protein partners and specific cellular pathways in the membrane and/or cytosolic districts such as endoplasmic reticulum/Golgi, axonal and synaptic compartments of dopaminergic neurons, that may cause the onset of neuronal cell dysfunction and degeneration which are among the key pathological features of the PD brain. Here we summarize a series of experimental data supporting that α-synuclein aggregation may induce dysfunction and degeneration of synapses via these multiple mechanisms. Taken together, these data add new insights into the complex mechanisms underlying synaptic derangement in PD and other α-synucleinopathies.

This article is part of a Special Issue entitled: Brain Integration.

Introduction

About 100 years after the publication of “An assay on Shaking Palsy” by James Parkinson in 1817, Friedrich Lewy first described the presence of intraneuronal spherical eosinophilic inclusions and thread-like neuroaxonal spheroids in the brain of Parkinson's disease (PD) patients. In a subsequent large-scale series of post-mortem examinations, Tretiakoff had found that the nucleus niger is most likely to be affected by what he called “corps de Lewy”. Nevertheless, Lewy had already described their diffuse and cortical distribution (Holdorff, 2002). Since that time, brain histopathologists have been largely engaged in the study of Lewy bodies (LB) in neuronal cell bodies and Lewy neuritis (LN) in neuronal processes in the brain of PD patients. A deeper histological analysis allowed to classify two main types of LB (Jellinger, 2009b): 1) classic brainstem LB are spherical cytoplasmic neuronal inclusions 8–30 μm in diameter with a hyaline eosinophilic core, centric lamellar bands and a narrow pale-stained halo. After ultrastructural analysis they result as membrane unbounded granulofilamentous structures. These are made up by radially arranged 7–20 nm intermediate filaments associated with granular electron-dense material and vesicular structures in a densely packed core with peripheral radially arranged filaments of 10 nm (Forno, 1996); 2) cortical LB are instead eosinophilic, rounded structures without halo which are poorly organized and composed by 7–27 nm wide filaments mostly devoid of a central core (Jellinger, 2009b).

The exact protein composition of LB remained unknown up to 1983, when Goldman et al. (1983) showed that they contained neurofilaments, as later confirmed by Schmidt et al. (1991). Subsequently, the ubiquitination of peripherally located filaments in LB was demonstrated (Kuzuhara et al., 1988, Lennox et al., 1989). Only in 1998 the main protein component of LB was identified by Spillantini et al. (1997). They found that LB are mainly constituted by fibrillary aggregates of α-synuclein, a presynaptic protein found to be mutated in some familial cases of the disease and whose function was still unknown at that time. Hence, much effort has been devoted to disclose whether α-synuclein modifications, aggregation and/or dysfunctions could be related to PD development as well as to other neurodegenerative diseases with LB pathology, such as dementia with LB (DLB), multiple system atrophy (MSA), LB dysphagia, Alzheimer's disease (AD) and its LB variant (LBVAD) (Dev et al., 2003, Spillantini and Goedert, 2000). Yet, despite the large amount of investigations aimed at defining the pathophysiological mechanisms underlying the onset of these disorders, their molecular basis still remain an unanswered conundrum.

Numerous studies have shown that α-synuclein has a critical role in the control of neuronal activity at synaptic sites. From the overview of the α-synuclein synaptic proteome and lipidome it can be inferred that α-synuclein plays central integrative functions in the brain. Indeed, it has been shown that it behaves like a molecular chaperone, interacts with lipid membranes and synaptic proteins, is involved in endoplasmic reticulum (ER)–Golgi and axonal transport and can be transmitted from cell to cell in a prion-like infective manner (Bellucci et al., 2012).

In this review, we focused our attention on recent relevant publications shading light upon a series of α-synuclein protein or lipid partners or specific α-synuclein-induced cellular pathways at both cytoplasmic, axonal or synaptic levels, which may be implicated in the onset of dopaminergic synaptic dysfunctions. By using the following keywords: α-synuclein/dopamine and synaptic dysfunction, synaptic plasticity, lipid membrane interactions, synaptic vesicle biogenesis and recycle, ER-to-Golgi vesicular transport, synaptic/axonal protein interaction we collected a series of experimental evidences supporting the hypothesis that α-synuclein pathology underlies the loss of a series of integrative neuronal functions which may significantly contribute to the induction of synaptic derangement in PD and possibly other α-synucleinopathies.

Section snippets

Structural characteristics of α-synuclein

Alpha-synuclein belongs to a family of genes which also includes β- and γ-synucleins. These proteins have a common N-terminal sequence containing a different number of repeat regions, while they differ in the C-terminal part (Bellucci et al., 2012). The sequence of α-synuclein gene (SNCA) has a high degree of conservation in numerous organisms (Clayton and George, 1998). In humans, three α-synuclein isoforms exist (Bayer et al., 1999). The most important and widely expressed isoform is the full

Parkinson's disease and other α-synucleinopathies

The term α-synucleinopathies is usually employed to describe a series of neurodegenerative diseases characterized by the presence of pathological lesions with fibrillary aggregated α-synuclein in neurons and glia. These include prevalent conditions such as PD, DLB and AD as well as rarer disorders such as MSA, neurodegeneration with brain iron accumulation type I (NBIA-I), pure autonomic failure or diffuse LB disease (Dev et al., 2003, Spillantini and Goedert, 2000, Uversky, 2007).

In these

Alpha-synuclein in synaptic physiology

Several experimental evidences support the idea that α-synuclein is able to alter synaptic physiology. In particular, a recent scientific report has described that mice lacking α-synuclein show an enhancement of a type of facilitation which reveals a form of short-term plasticity involving reorganization of pre-synaptic vesicular storage pools in the dorsal striatum: dopamine overflow following repeated, high-frequency burst stimulation of the dopaminergic pathways (Chadchankar and Yavich, 2011

Alpha-synuclein aggregation impairs synaptic activity by affecting specific molecular pathways as well as lipid and protein partners in distinct neuronal subcellular districts

In order to define whether and how α-synuclein may affect neuronal integrative functions in physiological and pathological conditions, it is essential to have a panorama of its proteome and lipidome. In particular, it seems that the specific regulatory effect of α-synuclein within the synaptic, axonal or ER–Golgi network might be lost following its pathological accumulation and aggregation. Indeed, a fine analysis of experimental data shed light upon a series of integrated pathological pathways

Cell-to-cell α-synuclein transmission: implications for synaptic dysfunctions

Post mortem evaluations have shown that the spreading of LB pathology correlates with the progression of PD, suggesting that α-synuclein increase and aggregation may contribute to neuronal degeneration (Braak et al., 2003, Halliday and McCann, 2010, Jellinger, 2009a). More recently, studies on autopsies from PD patients who had received implants from embryonic brain tissue, have shown that grafted neurons can develop LB-like aggregates a decade after transplantation, indicating that α-synuclein

Concluding remarks

From the evidences we have collected, we felt that in the human imagination α-synuclein behavior may be very similar to that of the “Sweet dancer” described by William Butler Yeats. She is an enchanting dancer. Even if you may think she is foolish following an unknown astray, you can't stop her, there's no way to understand her, other than let her finish her dance. Watching this dancer and her companions will give us much more than just halting the dance (Fig. 4 “Sweet dancer”).

Hence, to

Acknowledgments

This work was supported by a grant from the Italian Ministry of Education, University and Scientific ResearchPRIN 2006, by University of Brescia Research Fund EX 60% and by the Regione Lombardia, Italy NEDD Project (CUPH81J09002660007). We thank Dr. Alessandro Fanzani for reading the manuscript.

References (241)

  • D.R. Brown

    Metal binding to alpha-synuclein peptides and its contribution to toxicity

    Biochem. Biophys. Res. Commun.

    (2009)
  • H. Chadchankar et al.

    Sub-regional differences and mechanisms of the short-term plasticity of dopamine overflow in striatum in mice lacking alpha-synuclein

    Brain Res.

    (2011)
  • S. Chandra et al.

    A broken alpha-helix in folded alpha-synuclein

    J. Biol. Chem.

    (2003)
  • S. Chandra et al.

    Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration

    Cell

    (2005)
  • L. Chen et al.

    Proteasome dysfunction in aged human alpha-synuclein transgenic mice

    Neurobiol. Dis.

    (2006)
  • C.E. Chua et al.

    Rabs, SNAREs and alpha-synuclein — membrane trafficking defects in synucleinopathies

    Brain Res. Rev.

    (2011)
  • D.F. Clayton et al.

    The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease

    Trends Neurosci.

    (1998)
  • M. Colapinto et al.

    Alpha-synuclein protects SH-SY5Y cells from dopamine toxicity

    Biochem. Biophys. Res. Commun.

    (2006)
  • M.R. Cookson et al.

    Cell systems and the toxic mechanism(s) of alpha-synuclein

    Exp. Neurol.

    (2008)
  • R.A. Crowther et al.

    Synthetic filaments assembled from C-terminally truncated alpha-synuclein

    FEBS Lett.

    (1998)
  • J.G. Culvenor et al.

    Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid

    Am. J. Pathol.

    (1999)
  • E. Dalfo et al.

    Abnormal alpha-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease

    Neurobiol. Dis.

    (2004)
  • W.S. Davidson et al.

    Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes

    J. Biol. Chem.

    (1998)
  • G. De Franceschi et al.

    Structural and morphological characterization of aggregated species of alpha-synuclein induced by docosahexaenoic acid

    J. Biol. Chem.

    (2011)
  • M. Decressac et al.

    Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons

    Neurobiol. Dis.

    (2012)
  • K.K. Dev et al.

    Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease

    Neuropharmacology

    (2003)
  • D.W. Dickson et al.

    Widespread alterations of alpha-synuclein in multiple system atrophy

    Am. J. Pathol.

    (1999)
  • D. Eliezer et al.

    Conformational properties of alpha-synuclein in its free and lipid-associated states

    J. Mol. Biol.

    (2001)
  • W.P. Gai et al.

    In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies

    Exp. Neurol.

    (2000)
  • J.M. George et al.

    Characterization of a novel protein regulated during the critical period for song learning in the zebra finch

    Neuron

    (1995)
  • M. Goedert et al.

    The propagation of prion-like protein inclusions in neurodegenerative diseases

    Trends Neurosci.

    (2010)
  • A. Adamczyk et al.

    Alpha-synuclein potentiates Ca2 + influx through voltage-dependent Ca2 + channels

    Neuroreport

    (2006)
  • A. Aguzzi

    Cell biology: beyond the prion principle

    Nature

    (2009)
  • Z. Ahmed et al.

    Review: the neuropathology, pathophysiology and genetics of multiple system atrophy

    Neuropathol. Appl. Neurobiol.

    (2011)
  • H. Akiyama

    Abeta, tau and alpha-synuclein and glial cells

    Nihon Shinkei Seishin Yakurigaku Zasshi

    (2006)
  • S. Alais et al.

    Mouse neuroblastoma cells release prion infectivity associated with exosomal vesicles

    Biol. Cell

    (2008)
  • D. Albani et al.

    Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70

    FASEB J.

    (2004)
  • B. Alvarez-Castelao et al.

    Synphilin-1 inhibits alpha-synuclein degradation by the proteasome

    Cell. Mol. Life Sci.

    (2010)
  • C. Alves da Costa et al.

    Wild-type but not Parkinson's disease-related ala-53 → Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli

    J. Biol. Chem.

    (2000)
  • M. Baba et al.

    Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies

    Am. J. Pathol.

    (1998)
  • P. Barone

    Neurotransmission in Parkinson's disease: beyond dopamine

    Eur. J. Neurol.

    (2010)
  • T. Bartels et al.

    Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation

    Nature

    (2011)
  • S. Batelli et al.

    DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70

    PLoS One

    (2008)
  • T.A. Bayer et al.

    Neural expression profile of alpha-synuclein in developing human cortex

    Neuroreport

    (1999)
  • A.C. Belin et al.

    Parkinson's disease: a genetic perspective

    FEBS J.

    (2008)
  • S. Bellani et al.

    The regulation of synaptic function by alpha-synuclein

    Commun. Integr. Biol.

    (2010)
  • A. Bellucci et al.

    Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation

    J. Neurochem.

    (2008)
  • A. Bellucci et al.

    Redistribution of DAT/alpha-synuclein complexes visualized by “in situ” proximity ligation assay in transgenic mice modelling early Parkinson's disease

    PLoS One

    (2011)
  • A. Bellucci et al.

    Induction of the unfolded protein response by alpha-synuclein in experimental models of Parkinson's disease

    J. Neurochem.

    (2011)
  • E. Bertrand

    Type I neurodegeneration with brain iron accumulation, (NBIA-I, formerly Hallervorden–Spatz disease). Part II — neuropathologic manifestation, novel genetic aspects and pathogenesis

    Neurol. Neurochir. Pol.

    (2002)
  • Cited by (88)

    • Genes and dietary metals in Parkinson's disease

      2023, Vitamins and Minerals in Neurological Disorders
    • Neurotoxic or neuroprotective: Post-translational modifications of α-synuclein at the cross-roads of functions

      2022, Biochimie
      Citation Excerpt :

      Among all, the lag phase acts as a rate-limiting step as some of the major structural alterations take place during it. The lag phase is the only thermodynamically favored phase because the protein becomes compacted during fibril formation, culminating in reducing the overall exposed surface [41,42]. The fibrillization is a multi-stage process, starting from the monomeric stage, progressing to the oligomeric stage, followed by protofibrils, and ending with the formation of the fibrils.

    View all citing articles on Scopus
    View full text